UK:
Medical Device Issuer Becomes First Regulation A+ Issuer To Seek NYSE Market Listing
14 September 2017
Withers LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Myomo, Inc., a medical device company specializing in orthotics,
is hoping to become the first Regulation A+ issuer to be listed on
the New York Stock Exchange's small-cap market (NYSE MKT). In
its offering statement for a Regulation A+ offering, which has been
qualified by the SEC, Myomo disclosed its intent to apply to list
its common stock on the NYSE MKT.
Before Myomo may commence trading on the NYSE MKT, the offering
must be completed, Myomo must file a post-qualification amendment
to the offering statement and Form 8-A registration statement, and
the SEC must qualify such post-qualification amendment.
For more information, see
here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Finance and Banking from UK
FCA's Consultation Paper
Cadwalader, Wickersham & Taft LLP
Since 3 January 2018, firms that provide portfolio management or investment advice on an independent basis must pay for the research they obtain...
Regulation Round Up
Proskauer Rose LLP
Welcome to the UK Regulation Round Up, a regular bulletin highlighting the latest developments in UK and EU financial services regulation.
FCA To Permit Research Bundling
Akin Gump Strauss Hauer & Feld LLP
The Financial Conduct Authority (FCA) is seeking views on proposed rules that would allow asset managers to opt for bundled payments for third-party investment research, reversing a significant aspect of the UK's implementation of research rules under the Markets in Financial Instruments Directive (MiFID II).